Since SGLT2 inhibitors beneficially influence many factors that contribute to the development of complications of obesity it appears justified to assume that patients with obesity and an indication for SGLT2 inhibitors will especially benefit from treatment with a member of this drug class. This evidence concerns the gene SLC5A2 and Obesity.